Yao Jeffrey K, van Kammen Daniel P
VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania 15206, USA.
Int Rev Neurobiol. 2004;59:297-326. doi: 10.1016/S0074-7742(04)59012-8.
Although the potential key role that lipids may have in schizophrenia is not fully understood, multiple lines of evidence to date implicate the lipid environment in the behavior of neurotransmitter systems. Decreased phospholipid polyunsaturated fatty acids (PUFAs) have been demonstrated in both brain and peripheral membranes in schizophrenia, which is consistent with the hypothesis of myelin-related dysfunction in schizophrenia. Membrane defects, such as those induced by decreased PUFAs in phospholipids, can significantly alter a broad range of membrane functions and ipso facto behavior through multiple "downstream" effects. A number of putative mechanisms have been identified to explain the decreased PUFAs in schizophrenia, notably the increased turnover of phospholipids and decreased incorporation of arachidonic acid (AA) in membranes. In addition to increased oxidative stress, altered immune function may also be responsible for increased phospholipase activities. This association is particularly relevant in relation to phospholipids/PUFA, as AA can be converted to a variety of biologically active compounds, such as eicosanoids, which serve as potent messengers in regulating the inflammatory response, as well as endocannabinoids, which may affect schizophrenic psychopathology. Direct evidence of immune changes in some patients with schizophrenia have come to light, particularly in the activities of several cytokines known to be altered in autoimmune dysfunction. Given the diverse physiological function of AA, the specific behavioral symptomatology of schizophrenia is related mostly to the effect of AA changes that regulates neurodevelopment, neurotransmitter homeostasis, phosphatidylinositol signaling, and neuromodulatory actions of endocannabinoids in schizophrenia. Hence, in the current conceptualization, AA may be at a nexus point in the cascade leading to the syndrome of schizophrenia and represents a common biochemical pathway leading to the varied symptomatology of this disorder.
尽管脂质在精神分裂症中可能发挥的潜在关键作用尚未完全明确,但迄今为止的多条证据表明脂质环境与神经递质系统的行为有关。在精神分裂症患者的大脑和外周膜中均已证实磷脂多不饱和脂肪酸(PUFAs)减少,这与精神分裂症中髓鞘相关功能障碍的假说一致。膜缺陷,如磷脂中PUFAs减少所引发的那些缺陷,可通过多种“下游”效应显著改变广泛的膜功能及行为。已确定了一些推测机制来解释精神分裂症中PUFAs减少的现象,尤其是磷脂周转率增加以及膜中花生四烯酸(AA)掺入减少。除了氧化应激增加外,免疫功能改变也可能导致磷脂酶活性增加。这种关联在磷脂/PUFAs方面尤为相关,因为AA可转化为多种生物活性化合物,如类花生酸,其作为强效信使调节炎症反应,以及内源性大麻素,其可能影响精神分裂症的精神病理学。一些精神分裂症患者免疫变化的直接证据已被发现,特别是在已知在自身免疫功能障碍中发生改变的几种细胞因子的活性方面。鉴于AA具有多种生理功能,精神分裂症的特定行为症状大多与AA变化的影响有关,这些变化调节了精神分裂症中的神经发育、神经递质稳态、磷脂酰肌醇信号传导以及内源性大麻素的神经调节作用。因此,在当前的概念框架中,AA可能处于导致精神分裂症综合征的级联反应的交汇点,并且代表了导致该疾病多种症状的共同生化途径。